Series C Shares: Issue, Repurchase, Reclassification, and LTIP 2024 Transfer

On May 30, 2024, Medivir AB (publ) ("Medivir") announced several resolutions in alignment with the incentive program (LTIP 2024) approved by its annual general meeting on May 7, 2024. The board of directors has decided to issue 1,700,000 shares of series C, repurchase these shares, reclassify 114,587 of them into ordinary shares, and partially execute the transfer of 126,000 ordinary shares to participants in LTIP 2024.

Aktieinvest FK AB will subscribe to the 1,700,000 series C shares at SEK 0.5 per share, which matches the shares' quota value. Medivir will then repurchase all the issued series C shares at the same price of SEK 0.5 per share.

The objective behind this share issue and repurchase is to facilitate the acquisition of ordinary shares by participants in LTIP 2024, ensure the delivery of shares, and cover social costs and dividend compensations associated with LTIP 2024. A total of 114,587 shares of series C will be reclassified into ordinary shares. These, along with 11,413 existing ordinary shares, will make up the 126,000 ordinary shares to be transferred to LTIP 2024 participants as Investment Shares. The remaining series C shares will be retained by Medivir until they are needed for reclassification and transfer according to LTIP 2024 terms. Notably, series C shares are not entitled to dividends.

Before these transactions, Medivir held 11,413 ordinary shares and 864,750 series C shares. After repurchasing the 1,700,000 newly issued series C shares and transferring 11,413 existing ordinary shares plus 114,587 reclassified series C shares, Medivir will have zero ordinary shares and 2,450,163 series C shares.

Medivir specializes in developing innovative cancer drugs addressing high unmet medical needs. The company's drug candidates are aimed at areas with limited or no existing treatments, providing significant improvements for patients. Medivir's primary focus is on fostroxacitabine bralpamide (fostrox), a targeted chemotherapy designed to selectively treat liver cancer cells while minimizing side effects. Collaborations and partnerships are integral to Medivir's business model, and its drug development is conducted either independently or through partnerships. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!